Pharmacokinetics and biodistribution of Photolon® (Fotolon®) in intact and tumor-bearing rats

被引:18
作者
Shliakhtsin, S. V. [1 ]
Trukhachova, T. V.
Isakau, H. A.
Istomin, Y. P. [2 ]
机构
[1] RUE Belmedpreparaty, Dept Pharmacol & Toxicol, Minsk 220007, BELARUS
[2] NN Alexandrov Natl Canc Ctr Belarus, Minsk 223040, BELARUS
关键词
Photolon (R); Biodistribution; Blood-brain barrier; Pharmacokinetics; PHOTODYNAMIC THERAPY; CHLORIN; ACCUMULATION;
D O I
10.1016/j.pdpdt.2009.04.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This paper provides the results of the non-clinical evaluation of biodistribution of the PS Phototon (R) in inner organs and tissues of intact and tumor-bearing rats with xenograft tumors of different morphologic types. Methods: The accumulation studies were performed in rats by means of intravital laser fluorimetry in situ and spectrophotometric determination ex vivo. Results: The biodistribution pattern of Phototon (R) does not depend on tumor carriage as well as on morphologic type of the xenograft tumor. We have also showed that Phototon (R) easily crosses an intact blood-brain barrier and accumulates in tissues of central nervous system. The relative bioavailability of brain tissues for Photolon (R) was estimated as 82%, T-max-30 min, mean residual, time (MRT)-1.6 h. Conclusions: In general, results of the experimental study of biodistribution of Photolon (R) in inner organs and tissues of rats, performed as in real time (by means of intravital. laser fluorimetry in situ) as ex vivo (spectrophotometric assay) can be utilized while optimizing existing regimens of PDT with the purpose to increase safety and efficacy of treatment as well as for the development of new PDT protocols with Phototon (R) applied for new indications. Parameters of pharmacokinetics and biodistribution of Phototon (R)/Fotolon (R) as welt as its' ability to cross an intact blood-brain barrier, are optimal for the majority of modern clinical applications of PDT. Crown Copyright (C) 2009 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:97 / 104
页数:8
相关论文
共 24 条
[1]  
Blant SA, 2000, PHOTOCHEM PHOTOBIOL, V71, P333
[2]   Determination of the maximal tumor/normal skin ratio after HpD or m-THPC administration in hairless mouse (SKh-1) by fluorescence spectroscopy - A non-invasive method [J].
Bossu, E ;
AAmar, O ;
Parache, RM ;
Notter, D ;
Labrude, P ;
Vigneron, C ;
Guillemin, F .
ANTI-CANCER DRUGS, 1997, 8 (01) :67-72
[3]   Mechanisms in photodynamic therapy: Part three- Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction [J].
Castano, Ana P. ;
Demidova, Tatiana N. ;
Hamblin, Michael R. .
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2005, 2 (02) :91-106
[4]  
CHEUNG R, 2005, J BIOMED OPT, V8, P248
[5]   Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer [J].
Chin, William Wei Lim ;
Heng, Paul Wan Sia ;
Thong, Patricia Soo Ping ;
Bhuvaneswari, Ramaswamy ;
Hirt, Werner ;
Kuenzel, Sebastian ;
Soo, Khee Chee ;
Olivo, Malini .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 69 (03) :1083-1093
[6]   Foscan® uptake and tissue distribution in relation to photodynamic efficacy [J].
Cramers, P ;
Ruevekamp, M ;
Oppelaar, H ;
Dalesio, O ;
Baas, P ;
Stewart, FA .
BRITISH JOURNAL OF CANCER, 2003, 88 (02) :283-290
[7]  
*FOSC, EUR PUBL ASS REP REV
[8]   LIPID-ACCUMULATION - THE COMMON FEATURE TO PHOTOSENSITIZER-RETAINING NORMAL AND MALIGNANT-TISSUES [J].
FREITAS, I .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1990, 7 (2-4) :359-361
[9]  
GYNEATULLIN RU, 2008, B NOVEL MED TECHNOL, V3, P64
[10]   HOW DOES PHOTODYNAMIC THERAPY WORK [J].
HENDERSON, BW ;
DOUGHERTY, TJ .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1992, 55 (01) :145-157